With 0.71 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.85 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.73 whereas the lowest price it dropped to was $3.545. The 52-week range on MGX shows that it touched its highest point at $12.74 and its lowest point at $1.61 during that stretch. It currently has a 1-year price target of $16.50.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MGX was down-trending over the past week, with a drop of -4.81%, but this was up by 91.40% over a month. Three-month performance surged to 76.24% while six-month performance fell -18.91%. A look at the trailing 12-month EPS for MGX yields -2.50 with Next year EPS estimates of -2.66. For the next quarter, that number is -0.75. This implies an EPS growth rate of 87.64% for this year and -7.39% for next year.
Float and Shares Shorts:
At present, 37.43 million MGX shares are outstanding with a float of 18.78 million shares on hand for trading. On 2024-12-13, short shares totaled 1.48 million, which was 396.00000000000006 higher than short shares on 1731628800. In addition to Dr. Brian Charles Thomas Ph.D. as the firm’s Co-Founder, CEO & Chairman of the Board, Dr. Jian Irish M.B.A., Ph.D. serves as its President, COO & Director.
Institutional Ownership:
Through their ownership of 0.34682 of MGX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, MGX reported revenue of $11514000.0 and operating income of -$22383000.0. The EBITDA in the recently reported quarter was -$18964000.0 and diluted EPS was -$0.51.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MGX since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MGX analysts setting a high price target of 25.0 and a low target of 14.0, the average target price over the next 12 months is 18.4. Based on these targets, MGX could surge 602.25% to reach the target high and rise by 293.26% to reach the target low. Reaching the average price target will result in a growth of 416.85% from current levels.
Analysts have provided yearly estimates in a range of -$2.18655 being high and -$2.67021 being low. For MGX, this leads to a yearly average estimate of -$2.47876.
